stockportfolio.pro
Biogen Inc. P/E Ratio 2007–2025
Biogen Inc. (BIIB) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth -2.0%/yr over 18 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 20.02 | +46.4% |
| FY 2024 | 13.68 | -57.9% |
| FY 2023 | 32.47 | +144.7% |
| FY 2022 | 13.27 | -42.5% |
| FY 2021 | 23.07 | +133.7% |
| FY 2020 | 9.87 | +4.5% |
| FY 2019 | 9.44 | -32.3% |
| FY 2018 | 13.94 | -47.8% |
| FY 2017 | 26.73 | +59.6% |
| FY 2016 | 16.75 | -16.1% |
| FY 2015 | 19.97 | -27.2% |
| FY 2014 | 27.44 | -23.3% |
| FY 2013 | 35.80 | +40.9% |
| FY 2012 | 25.41 | +16.4% |
| FY 2011 | 21.84 | +28.3% |
| FY 2010 | 17.02 | +6.6% |
| FY 2009 | 15.97 | -11.1% |
| FY 2008 | 17.97 | -37.2% |
| FY 2007 | 28.60 | — |
Source: Biogen Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Biogen Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBiogen Inc. — frequently asked questions
What is Biogen Inc.'s price-to-earnings ratio?
Biogen Inc. (BIIB) reported price-to-earnings ratio of 20.02 for fiscal year 2025, per its SEC filings.
How has Biogen Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2007 and 2025, BIIB's price-to-earnings ratio declined at roughly 2.0% per year (compound annual rate), from 28.60 to 20.02.
Where does this data come from?
Figures are computed from Biogen Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.